12 Sep

What Analysts Recommend for HEXO

WRITTEN BY Adam Jones

Hydropothecary

HEXO got a boost on Thursday following a letter from its second-largest shareholder, expressing concerns over depressed valuations despite relatively strong fundamentals and revenue visibility. Hydropothecary is another company (MJ) to form a partnership with alcoholic beverage company Molson Coors Brewing (TAP). Canopy Growth (CGC)(WEED) was the first Canadian company to form such a partnership with Constellation Brands (STZ).

What Analysts Recommend for HEXO

Analysts’ recommendation

The overall consensus recommendation for Hydropothecary is a “buy,” which remained unchanged from last month. A total of two analysts maintained their “strong buy” recommendation on the stock in September and five analysts maintained a “buy” recommendation on the stock. The stock didn’t have any “hold” recommendations or “sell” recommendations.

Price target

The consensus price target on the company remained unchanged in the current month, which was similar to the trend in the recommendation. The current consensus price target for Hydropothecary stood at 8.6 Canadian dollars. As of September 11, HEXO was trading at 8.5 Canadian dollars, which was close to the consensus price target on the company for the next 12 months.

Next, we’ll discuss the recommendations and price target for CannTrust (CNTTF).

Latest articles

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

In the November 14 trading session, Aurora Cannabis (ACB) stock fell 12.7% from the previous session during after-hours trading.

Strategy Analytics reported that Apple could lead the 5G smartphone market in 2020, outshining Samsung—the current leader in the global 5G market.

This week has been tough for the cannabis sector. Cronos Group and Canopy Growth reported lower-than-expected earnings, and the sector ETFs dropped.

Yesterday, Argus Research upgraded Uber stock from “hold” to “buy.” Let's look at Uber and Lyft’s recent analyst rating changes.